«This is encouraging because the
safety profile of anti-muscarinic drugs is well -
characterized, with more than 20 years of clinical application for a variety of indications in Europe,» said senior study author Paul Fernyhough, PhD, professor in the departments of pharmacology and therapeutics and physiology at the University of Manitoba in Canada.